At the same time, the whole pharmaceutical and vaccine sector also collapsed. Intech group and Weiming medicine also fell to the limit, and the vaccine index fell by nearly 5%, ranking the first in the decline.
40000 shareholders are confused: Zhengchuan shares fall again!
Today, Zhengchuan shares closed down 10% and the stock price was 78.17 yuan. The capital was trying to flee, with a turnover rate of 9.85%. Up to the end of the day, there were 15500 hands of funds that could not be sold on the limit board.
It is worth noting that yesterday Zhengchuan shares just soared to 103 yuan. However, at the end of the day, Zhengchuan shares were cut off. On October 21, Zhengchuan shares jumped from 102.52 yuan at 14:45 and dropped to 85.27 yuan at 14:50, down nearly 17% in six minutes, and the turnover rate reached 13.88% yesterday.
This means that in less than two days, they ate a bowl of 25% noodles. The market value of Zhengchuan shares evaporated by nearly 5 billion in two days.
As a result, todays shares of Zhengchuan shares are simply blown up. Shareholders are crying about how much money they lost in 2 days.
Many investors who pursue high said that those who had entered more than 100 would have wanted to pursue high, but they lost nearly 25% in two days.
According to wind data, the latest shareholder number of Zhengchuan is 43000.
The stock price doubled in the past month
Zhengchuan Co., Ltd. is a garden enterprise specializing in the production of pharmaceutical glass tube bottles and supporting production of pharmaceutical bottle caps. Zhengchuans main business is pharmaceutical manufacturing, accounting for more than 99% of its revenue.. Zhengchuan stock is a big bull stock this year. Before yesterdays plunge, the share price of Zhengchuan shares in nearly 21 trading days had soared from 46 yuan to 103 yuan, which had already doubled.
As of October 21, the companys stock rolling P / E ratio was 223.76, and the static P / E was 234.56, which was much higher than that of the medical device industry (59.29) and static P / E of 60.05.
The company announced that the companys current production and operation activities are normal. At present, a medium boron glass tube furnace of the company is in the construction stage, and there is no formal mass production. Even if the production is officially carried out, the production is relatively limited, and the market share is not high in the short term. At the same time, the consistency evaluation carried out by the state, the stability test of drug packaging materials and so on need to be verified for a long time. It is uncertain whether the self-made borosilicate glass tube can be used for vaccine in the future.
Mystery man reminds stop profit out before plummeting
Dragon and tiger list shows hot money fighting
It is worth noting that there are chat records flowing out of the network. The screenshot shows that, before the sharp fall of Zhengchuan shares yesterday, a user in a wechat group prompted all the current prices of Zhengchuan shares to stop earning at 14:42, while the stock price of Zhengchuan shares collapsed at 14:44.
From the dragon and tiger list after yesterdays plate, the buyer and seller of Zhengchuan shares are fighting for hot money. There are three business departments of Dongfang Fortune Securities in Lhasa for the buyer, and there are two business departments of Dongfang Fortune Securities in Lhasa in the seller. Dongcai Lhasa business department is recognized as a hot money seat. At the same time, the sellers second seat is the well-known hot money seat Guosheng securities Ningbo Sangtian road, which sold more than 33 million yuan.
Intech and Weiming medicine both drop limit
In addition to Zhengchuan shares, pharmaceutical, vaccine and other concept index led the market down. Among them, the vaccine index plummeted by 4.76%, and the biological vaccine index fell by 2.5%.
And Intech group, Weiming medicine also fell. Kanghua biological also fell more than 10%.
Death cases of vaccination in South Korea and Brazil
No serious adverse reactions have been reported in China
From the global point of view, there are a lot of International Vaccine news recently.
From the current global influenza vaccination situation, some countries in South Korea and Brazil have gradually appeared the death cases of vaccination.
According to the South Korea disease management agency on October 20, there were two cases of death after influenza vaccination in South Korea: a 78 year old woman died one day after receiving the flu vaccine in Gaochang County, North Jeong Road, and an 82 year old man in Daejeon City died hours after receiving the flu vaccine on the 20th. In addition, a 17-year-old boy in Incheon city died two days after being vaccinated with influenza vaccine on the 14th, which raised doubts about the safety of the flu vaccine among South Korean people. South Koreas disease management agency said whether there is a causal relationship between vaccination and deaths has not been determined, and relevant departments are investigating. Up to now, 32 people who have received the same batch of vaccines in the same medical institution as Incheons 17-year-old have not had any adverse reactions.
According to the globe, the dead volunteer was a 28 year old male doctor who has been working in a hospital in Rio since March this year and has been fighting in the forefront of the fight against the disease. Novel coronavirus pneumonia was reported to be in good health. In late July, the vaccine developed jointly by University of Oxford and AstraZeneca was inoculated in September. The new crown virus was contracted in September this year. Unfortunately, the new crown pneumonia and complications were unfortunate. It is not known whether the volunteer was vaccinated or placebo.
In June this year, a vaccine jointly developed by Oxford University and AstraZeneca launched a phase III clinical trial in Brazil. So far, 8000 volunteers have participated in the study in Brazil. Earlier, Brazilian president bosonaro signed an interim measure allowing the federal government to allocate 1.9 billion reais (about 2.2 billion yuan) to buy 100 million doses of Oxford vaccine. However, no serious adverse reactions have been reported in China. Wu Guizhen, chief biosafety expert of China Center for Disease Control and prevention: all vaccines may have adverse reactions, but the adverse reactions can be divided into different degrees and grades. Generally speaking, there are mild, moderate and severe adverse reactions. At present, there are no reports of serious adverse reactions from the new coronal vaccine in China. These general adverse reactions are within the normal range after vaccination, so its safety is good. Source: Zhong Qiming, editor in charge of China fund daily_ NF5619
In June this year, a vaccine jointly developed by Oxford University and AstraZeneca launched a phase III clinical trial in Brazil. So far, 8000 volunteers have participated in the study in Brazil. Earlier, Brazilian president bosonaro signed an interim measure allowing the federal government to allocate 1.9 billion reais (about 2.2 billion yuan) to buy 100 million doses of Oxford vaccine.
However, no serious adverse reactions have been reported in China.